Your browser doesn't support javascript.
loading
PK-DB: pharmacokinetics database for individualized and stratified computational modeling.
Grzegorzewski, Jan; Brandhorst, Janosch; Green, Kathleen; Eleftheriadou, Dimitra; Duport, Yannick; Barthorscht, Florian; Köller, Adrian; Ke, Danny Yu Jia; De Angelis, Sara; König, Matthias.
Afiliación
  • Grzegorzewski J; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
  • Brandhorst J; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
  • Green K; Department of Biochemistry, University of Stellenbosch, Van der Byl Street, Stellenbosch 7600, South Africa.
  • Eleftheriadou D; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
  • Duport Y; Department of Mathematics and Computer Science, Freie Universität Berlin, Arnimallee 14, Berlin 14195, Germany.
  • Barthorscht F; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
  • Köller A; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
  • Ke DYJ; Department of Biology, University of Ottawa, Ottawa, ON, Canada.
  • De Angelis S; King's College London, Department of Biomedical Engineering & Imaging Sciences, London, UK.
  • König M; Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.
Nucleic Acids Res ; 49(D1): D1358-D1364, 2021 01 08.
Article en En | MEDLINE | ID: mdl-33151297
ABSTRACT
A multitude of pharmacokinetics studies have been published. However, due to the lack of an open database, pharmacokinetics data, as well as the corresponding meta-information, have been difficult to access. We present PK-DB (https//pk-db.com), an open database for pharmacokinetics information from clinical trials. PK-DB provides curated information on (i) characteristics of studied patient cohorts and subjects (e.g. age, bodyweight, smoking status, genetic variants); (ii) applied interventions (e.g. dosing, substance, route of application); (iii) pharmacokinetic parameters (e.g. clearance, half-life, area under the curve) and (iv) measured pharmacokinetic time-courses. Key features are the representation of experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, a workflow for collaborative data curation, strong validation rules on the data, computational access via a REST API as well as human access via a web interface. PK-DB enables meta-analysis based on data from multiple studies and data integration with computational models. A special focus lies on meta-data relevant for individualized and stratified computational modeling with methods like physiologically based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD), or population pharmacokinetic (pop PK) modeling.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Modelos Estadísticos / Bases de Datos Factuales / Medicamentos bajo Prescripción / Anotación de Secuencia Molecular Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Modelos Estadísticos / Bases de Datos Factuales / Medicamentos bajo Prescripción / Anotación de Secuencia Molecular Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2021 Tipo del documento: Article País de afiliación: Alemania